Moderna, Inc. — MRNA

Close PriceMarket CapP/E RatioForward P/E RatioImplied Growth*Implied Forward Growth*DividendP/B Ratio
$24.54$9.59B--2.8N/A--1.0

Revenue & Net Income

Revenue & Net Income
  Date Revenue Net Income EPS Revenue Change Net Income Change EPS Change
0 2020-12-31 $274.0M $-747.0M $-1.96 N/A N/A N/A
1 2021-12-31 $17.7B $12.2B $30.31 6373.0% -1733.5% -1646.4%
2 2022-12-31 $18.9B $8.4B $21.26 6.4% -31.5% -29.9%
3 2023-12-31 $6.8B $-4.7B $-12.33 -64.2% -156.4% -158.0%
4 2024-12-31 $3.2B $-3.6B $-9.28 -52.6% -24.5% -24.7%
5 TTM 2025-03-31 $3.1B $-3.4B $-8.73 -1.9% -5.7% -5.9%
6 Average 1252.1% -390.3% -373.0%

EPS

EPS

Forecasts

Revenue/Net Income Forecast EPS Forecast

Y/Y % Change

Revenue YoY Change EPS YoY Change
YoY Growth Rates

MRNA Year-over-Year Growth

  2020 2021 2022 2023 2024 2025 2026 Average
Revenue Growth (%) 6373.0% 6.4% -64.2% -52.6% -40.6% 31.1% 1042.2%
Revenue Analysts (#) 0 0 0 0 0 8 8
EPS Growth (%) -1733.5% -31.5% -156.4% -24.5% 5.1% -24.0% -327.5%
EPS Analysts (#) 0 0 0 0 0 9 9

Expenses

Revenue vs Expenses Expenses % of Revenue
Year Revenue ($) Cost of Revenue ($) R&D ($) SG&A ($) Facilities / D&A ($)
2021 $17.7B $2.4B $2.0B $567.0M $232.0M
2022 $18.9B $5.1B $3.3B $1.1B $348.0M
2023 $6.8B $4.1B $4.8B $1.5B $621.0M
2024 $3.2B $1.3B $4.5B $1.2B $189.0M
TTM $3.1B $1.3B $3.8B $1.1B $208.0M
Year Revenue Change (%) Cost of Revenue Change (%) R&D Change (%) SG&A Change (%) Facilities / D&A Change (%)
2022 6.42 112.49 65.49 99.65 50.00
2023 -64.22 -19.65 47.04 36.84 78.45
2024 -52.64 -68.69 -6.23 -24.21 -69.57
TTM -4.50 -1.65 -16.02 -8.52 10.05
No unmapped expenses.

Segment Performance

SEGMENTS v2025-09-09 · 2025-11-10 08:26 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
Year Product Sales Rev Product Sales OI C O V I D19 Rev C O V I D19 OI Product And Service Other Rev Product And Service Other OI Grant Rev Grant OI Collaboration Arrangement Including Arrangements With Affiliate Rev Collaboration Arrangement Including Arrangements With Affiliate OI Other Revenue Rev Other Revenue OI License And Royalty Rev License And Royalty OI R S V Rev R S V OI Total Rev Total OI
2022 92.2B 0.00B 18.4B 0.00B 1.66B 0.00B 1.16B 0.00B 1.32B 0.00B 114.8B 0.00B
2023 33.4B 0.00B 6.67B 0.00B 0.35B 0.00B 0.28B 0.00B 0.25B 0.00B 40.9B 0.00B
2024 15.5B 0.00B 3.08B 0.00B 0.28B 0.00B 0.29B 0.00B 0.14B 0.00B 0.04B 0.00B 0.03B 0.00B 19.4B 0.00B
TTM 6.32B 0.00B 1.25B 0.00B 0.25B 0.00B 0.11B 0.00B 0.10B 0.00B 0.07B 0.00B 0.01B 0.00B 0.01B 0.00B 8.12B 0.00B
% of Total (TTM) 77.8% 15.4% 3.0% 1.4% 1.2% 0.9% 0.2% 0.1% 100%

No segment data available for MRNA (axis 2).

Balance Sheet

Balance Sheet
  Metric Value
0 Total Assets $12,010M
1 Cash $1,279M
2 Total Liabilities $2,611M
3 Total Debt $741M
4 Total Equity $9,399M
5 Debt to Equity Ratio 0.08

EPS & Dividend

EPS & Dividend

Valuation

Valuation
Share Price Treasury Yield Estimates Fair Value (P/E) Fair Value (P/S) Current P/S
$25.90 4.4% Nicks Growth: 8%
Nick's Expected Margin: 10%
FINVIZ Growth: 21%
Nicks: 14
Finviz: 45
Nick's: 1.428 3.2
Basis Year Nicks Valuation Nicks vs Share Price Finviz Valuation Finviz vs Share Price
$8.12 RevPS TTM $11.59 -55.3% $36.88 42.4%
$5.38 RevPS 2025 $7.68 -70.3% $24.44 -5.6%
$6.72 RevPS 2026 $9.60 -62.9% $30.55 18.0%

Implied Growth

Implied Growth
No implied growth data available.

← Back